Diwali Samvat 2082 Stock Pick: Windlas Biotech Ltd – MNCL’s Top Choice

Windlas Biotech Ltd. (WBL) is one of the leading domestic Contract Development and Manufacturing Organizations (CDMOs) in India, specializing in formulation development and manufacturing for pharmaceutical companies. The company operates across three key verticals — CDMO, Trade Generics, and Exports — with CDMO contributing the majority of revenues. Over the years, Windlas has established strong relationships with marquee clients in the Indian pharmaceutical market and built a solid track record of product innovation, regulatory compliance, and operational excellence. The company’s recent entry into the injectables segment further strengthens its dosage-form capabilities and positions it to capitalize on rising outsourcing and premiumization trends in Indian formulations. With the domestic CDMO industry projected to grow at 12–14% CAGR over FY25–28E and outsourcing penetration expected to increase from 32% to 39% by FY28, Windlas is well placed to deliver robust growth over the medium term.

Source: ACE Equity, MNCL Research

Price Performance

Source: ACE Equity, MNCL Research

Shareholding Pattern

Source: ACE Equity, MNCL Research

Strong Leadership in Domestic CDMO Industry:

Windlas is one of the most integrated and compliant CDMO players serving leading domestic pharmaceutical companies. The CDMO segment is expected to grow at ~16% CAGR over FY25–28E, supported by steady addition of new customers, expansion of the product portfolio, and capacity enhancement through recent de-bottlenecking initiatives at Plant 2 (capex of ₹20–25 crore, expected to add ~₹100 crore in revenue potential).

Diversified Revenue Mix with Rising Share of High-Margin Segments:

Apart from the core CDMO business, the Trade Generics segment, currently the fastest-growing vertical, is expected to grow at ~20% CAGR by FY28E, supported by strong distribution expansion and government initiatives to expand Jan Aushadhi stores. The company’s recent foray into injectables (₹74 crore investment) adds a scalable, high-margin growth driver, expected to contribute over ₹100 crore in revenue by FY28E.

Margin Expansion and Robust Balance Sheet:

EBITDA margins are expected to expand from 12.4% in FY25 to 14.5% in FY28E, a ~200 bps increase, supported by a richer business mix, operating leverage, and contribution from high-margin injectables. Windlas maintains a strong balance sheet with ₹200 crore net cash (FY25), projected to reach ₹450 crore by FY28E, providing flexibility for both organic and inorganic growth. Return on capital employed (ROCE) is expected to rise to ~23% by FY28E as asset turnover normalizes.

Strategic Optionality from Inorganic Growth:

The revised Schedule M regulatory tightening is expected to create compliance challenges for smaller CDMO players, thereby opening consolidation opportunities. Windlas’s strong cash position enables it to pursue strategic bolt-on acquisitions or greenfield expansions, providing additional growth optionality.

Outlook & Valuation:

We believe Windlas is well positioned to benefit from structural growth tailwinds in India’s CDMO space, supported by its entry into high-value injectables and the fast-growing trade generics segment. A strong balance sheet, expanding client base, and improving margins are expected to underpin a sustainable growth trajectory. We assign a 15x FY27E EV/EBITDA multiple, implying a target price of Rs1,225 per share.

Exhibit 1: Key Financials (Consolidated)

Exhibit 2: Key Indicators

Source: Company Windlas Biotech Ltd, MNCL Research

STOCK PICKS FOR SAMVAT 2082

*Closing Price as on 10-10-2025

This Diwali, turn your wishes into wealth – Open your MNCL Demat Account today!

Disclaimer - Investments in securities market are subject to market risk, read all the related document carefully before investing.       
https://www.mnclgroup.com/research-disclaimer